Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205147 | 0.82 | BCHE (0.49) | BCHEKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL13006882 | 0.80 | KDM4E (0.48) | BCHEKDM4EPOLBHPGDHTT | |
| SCHEMBL1375400 | 0.79 | BCHE (0.62) | BCHEKDM4EPOLBHPGDHTT | |
| SCHEMBL19369746 | 0.79 | ALDH1A1 (0.40) | BCHEALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL1375397 | 0.78 | BCHE (0.57) | BCHEKDM4EPOLBHPGDHTT | |
| SCHEMBL14376841 | 0.78 | BCHE (0.69) | BCHEKDM4EPOLBHPGDHTT | |
| SCHEMBL3964578 | 0.77 | BCHE (0.36) | BCHEKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL12251552 | 0.77 | BCHE (0.50) | BCHEKDM4EPOLBHPGDHTT | |
| SCHEMBL4971987 | 0.76 | ALDH1A1 (0.36) | BCHEALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL21042943 | 0.76 | ALDH1A1 (0.49) | KDM4EPOLBALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | BCHE 851/4885KDM4E 4388/4885POLB 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.